Key Points A former pandemic favorite and a lesser-known biopharmaceutical stock both have value to add to a long-term investor's portfolio. Pfizer's growth has slowed from a few years ago, but its tepid stock price is not telling the whole story of this innovative company. Vertex Pharmaceuticals is rapidly expanding its portfolio in the rare-disease drug market, and growing its profits in the process. 10 stocks we like better than Pfizer › The healthcare industry revolves around constant innovat ...